Accordingly, when comparing TGFB1 expression between tumor and normal samples encompassing 22 blood cancer types, we found TGFB1 to be largely dysregulated in blood cancers: it was generally up-regulated in myeloid malignancies like AML, MDS, and CML and down-regulated in lymphoid leukemias (ALL and CLL) when compared to normal samples. The gene discussed is TGFB1; the disease is myelodysplastic syndrome.